Intellipharmaceutics International Inc. Share Price OTC Markets

Stocks

IPCI.Q

CA4581733090

Pharmaceuticals

OTC Markets Traded
Market Closed - OTC Markets 07:06:26 24/07/2026 pm IST 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Intellipharmaceutics International Inc. 0.00% -

Valuation: Intellipharmaceutics International Inc.

Market Cap 12.81L 11.25L 10.47L 10L 18.04L 12Cr 18.32L 1.24Cr 48.55L 6.07Cr 48.1L 47.06L 21Cr P/E 2021
-0.4x
P/E 2022 -0.91x
Enterprise Value 35.23L 30.95L 28.78L 26.41L 49.62L 34Cr 50.39L 3.42Cr 1.34Cr 17Cr 1.32Cr 1.29Cr 58Cr EV / Sales 2021
-
EV / Sales 2022 74x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
3 years 0
Extreme 0
0.15
5 years 0
Extreme 0
0.3
10 years 0
Extreme 0
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 01/04/2007
Corporate Officer/Principal - 01/02/2014
Director TitleAgeSince
Director/Board Member - 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 15.18L
+0.86%+1.43%+48.50%+160.39% 1,05700Cr
+1.59%+4.09%+55.34%+53.96% 62TCr
+0.95%+1.91%+35.91%+81.14% 45TCr
+1.60%+6.25%+33.95%+29.84% 34TCr
-0.60%+1.52%+35.68%+39.76% 30TCr
-0.14%+0.60%+16.17%+17.53% 26TCr
+0.09%-2.82%-28.29%-41.71% 22TCr
+1.22%+2.66%+21.87%+59.73% 20TCr
-1.18%-3.70%+14.23%+66.51% 16TCr
Average +0.33%+1.26%+25.93%+51.91% 40.16TCr
Weighted average by Cap. +0.54%+1.92%+35.73%+77.61%

Financials

2021 2022
Net sales - 65.73T 57.73T 53.69T 49.26T 92.56T 63.3L 93.99T 6L 2L 31.12L 2L 2L 1.08Cr
Net income -51.45L -45.19L -42.03L -38.56L -72.46L -50Cr -73.58L -4.99Cr -1.95Cr -24Cr -1.93Cr -1.89Cr -84Cr -28.92L -25.4L -23.63L -21.68L -40.73L -28Cr -41.36L -2.81Cr -1.1Cr -14Cr -1.09Cr -1.06Cr -47Cr
Net Debt 11.45L 10.06L 9L 9L 16.13L 11Cr 16.38L 1.11Cr 43.4L 5.42Cr 43L 42.07L 19Cr 22.42L 19.69L 18.31L 16.81L 31.58L 22Cr 32.06L 2.17Cr 84.97L 11Cr 84.17L 82.36L 37Cr
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
Date Price Change Volume